Androgen-deprivation therapy in prostate cancer: A European expert panel review

Keyphrases

• European Experts 100%
• Expert Panel 100%
• Prostate Cancer 100%
• Androgen Deprivation Therapy 100%
• Panel Review 100%
• Quality of Life 16%
• Serum Testosterone 16%
• High Risk 11%
• Adverse Events 11%
• Metastatic Disease 11%
• External Beam Radiotherapy 11%
• High-risk Disease 11%
• Bilateral Orchidectomy 11%
• Therapeutic Target 5%
• On-state Current 5%
• Clinical Application 5%
• Clinical Setting 5%
• Testosterone 5%
• Disease Risk 5%
• Clinical Implementation 5%
• Working Diagnosis 5%
• Clinical Benefit 5%
• Localized Disease 5%
• Patient Well-being 5%
• Local Therapy 5%
• Serious Complications 5%
• Radical Prostatectomy 5%
• Curative Treatment 5%
• Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 5%
• Symptom Development 5%
• Poor Prognostic Factors 5%
• European Association of Urology 5%
• Evidence Acquisition 5%
• Adverse Event Management 5%
• Optimal Timing 5%
• Biochemical Relapse 5%
• Node-positive Disease 5%
• Biochemical Progression 5%
• Symptomatic Progression 5%

Medicine and Dentistry

• Prostate Cancer 100%
• Androgen Deprivation Therapy 100%
• Quality of Life 22%
• Diseases 22%
• Adverse Event 16%
• External Beam Radiotherapy 11%
• Orchiectomy 11%
• Metastatic Carcinoma 5%
• Prognostic Factor 5%
• Localized Disease 5%
• Local Therapy 5%
• Prostatectomy 5%
• Biochemical Recurrence 5%
• Urology 5%

Pharmacology, Toxicology and Pharmaceutical Science

• Androgen 100%
• Prostate Cancer 100%
• Diseases 27%
• Adverse Event 16%
• Biochemical Recurrence 5%